MDT

86.73

-1.87%↓

120.12

-0.54%↓

VEEV

166.25

+4.78%↑

HQY

83.3

+3.65%↑

NEOG

9.45

0%↓

MDT

86.73

-1.87%↓

120.12

-0.54%↓

VEEV

166.25

+4.78%↑

HQY

83.3

+3.65%↑

NEOG

9.45

0%↓

MDT

86.73

-1.87%↓

120.12

-0.54%↓

VEEV

166.25

+4.78%↑

HQY

83.3

+3.65%↑

NEOG

9.45

0%↓

MDT

86.73

-1.87%↓

120.12

-0.54%↓

VEEV

166.25

+4.78%↑

HQY

83.3

+3.65%↑

NEOG

9.45

0%↓

MDT

86.73

-1.87%↓

120.12

-0.54%↓

VEEV

166.25

+4.78%↑

HQY

83.3

+3.65%↑

NEOG

9.45

0%↓

Home・Aktien・Lisata Therapeutics

L
Lisata Therapeutics

Open

4.19 -15.69

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

4.18

Max

4.82

Schlüsselkennzahlen
By Trading Economics
Einkommen	1.3M -3M
Verkäufe	100K 100K
Gewinnspanne	-2,954
Angestellte	21

Dividenden
By Dow Jones
Nächstes Ergebnis	7. Mai 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-208K 39M
Vorheriger Eröffnungskurs	19.88
Vorheriger Schlusskurs	4.19

Lisata Therapeutics Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

14. Apr. 2026, 23:36 UTC

Akquisitionen, Fusionen, Übernahmen

China-Backed Yancoal Australia to Buy Kestrel Coal Mine Stake For Up to $2.4 Billion -- Update

14. Apr. 2026, 23:24 UTC

Heiße Aktien

Stocks to Watch: Gloo, Broadcom, GitLab

14. Apr. 2026, 22:42 UTC

Akquisitionen, Fusionen, Übernahmen

China-Backed Yancoal Australia to Buy Kestrel Coal Mine Stake For Up to $2.4 Billion

14. Apr. 2026, 21:32 UTC

Wichtige Markttreiber

GitLab Shares Rise on Expanded Google Cloud Collaboration

14. Apr. 2026, 23:54 UTC

Market Talk

Nikkei May Rise as Fears About Energy Shortage Ease -- Market Talk

14. Apr. 2026, 23:34 UTC

Market Talk

Gold Edges Lower on Possible Technical Correction -- Market Talk

14. Apr. 2026, 22:54 UTC

Ergebnisse

BRP: Amendment Mainly Leads to 25% Tariff on Total Value of Imported Snowmobiles and Majority of ORV Models, Replacing Previous 50% Tariff on Applicable Metal Content Only >DOO.T

14. Apr. 2026, 22:54 UTC

Ergebnisse

BRP: Suspending Guidance Following Amendment of Section 232 Tariffs on Steel, Aluminum and Copper Imports Into U.S., Which Came Into Effect on April 6 >DOO.T

14. Apr. 2026, 22:54 UTC

Ergebnisse

BRP: Currently Estimates Potential Incremental Tariff Cost Related to This Amendment in Excess of $500M for Remainder of Yr >DOO.T

14. Apr. 2026, 22:54 UTC

Ergebnisse

BRP: Suspends FY27 Guidance Due to Changes to U.S. Tariff Environment

14. Apr. 2026, 22:17 UTC

Akquisitionen, Fusionen, Übernahmen

Yancoal Australia: Targets Deal Completion Toward End of 3Q

14. Apr. 2026, 22:17 UTC

Akquisitionen, Fusionen, Übernahmen

Yancoal Australia: Acquisition Diversifies Portfolio; Met Coal Share to Rise to 22%

14. Apr. 2026, 22:17 UTC

Akquisitionen, Fusionen, Übernahmen

Yancoal Australia: Asset 'Strong Strategic Fit'; to Positively Add Production, Cash Flow

14. Apr. 2026, 22:16 UTC

Akquisitionen, Fusionen, Übernahmen

Yancoal Australia: Intends to Fund Acquisition With Cash, 5-Year Loan Facility

14. Apr. 2026, 22:15 UTC

Akquisitionen, Fusionen, Übernahmen

Yancoal Australia: Contingent Consideration Linked to Average Annual Prices For 5 Years

14. Apr. 2026, 22:14 UTC

Akquisitionen, Fusionen, Übernahmen

Yancoal Australia: Deal Includes Contingent Cash Consideration Up to $550 Million

14. Apr. 2026, 22:13 UTC

Akquisitionen, Fusionen, Übernahmen

Yancoal Australia: Deal Includes $1.85 Billion Upfront Consideration

14. Apr. 2026, 22:12 UTC

Akquisitionen, Fusionen, Übernahmen

Yancoal Australia: To Buy Kestrel Stake From EMR Capital, Adaro Capital

14. Apr. 2026, 22:12 UTC

Akquisitionen, Fusionen, Übernahmen

Yancoal Australia: To Buy Kestrel Stake For Up to $2.4 Billion

14. Apr. 2026, 22:10 UTC

Akquisitionen, Fusionen, Übernahmen

Yancoal Australia: to Acquire 80% Interest in Kestrel Coal Mine

14. Apr. 2026, 20:50 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Basic Materials Roundup: Market Talk

14. Apr. 2026, 20:33 UTC

Akquisitionen, Fusionen, Übernahmen

Microsoft Is Buying 3,200 Acres For a Data Center. This Utility Stock Is Rising. -- Barrons.com

14. Apr. 2026, 20:32 UTC

Heiße Aktien

Stocks to Watch: JPMorgan, American Airlines, LVMH, BlackRock -- WSJ

14. Apr. 2026, 19:59 UTC

Akquisitionen, Fusionen, Übernahmen

Microsoft Is Buying 3,200 Acres For a Data Center. This Utility Stock Is Rising. -- Barrons.com

14. Apr. 2026, 19:38 UTC

Ergebnisse

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14. Apr. 2026, 19:27 UTC

Market Talk

U.S. Natural Gas Futures Extend Losing Streak -- Market Talk

14. Apr. 2026, 19:21 UTC

Market Talk

Wichtige Nachrichtenereignisse

Oil Futures Retreat on Hopes for U.S.-Iran Peace Talks -- Market Talk

14. Apr. 2026, 19:09 UTC

Akquisitionen, Fusionen, Übernahmen

Apple and Amazon Partner on Satellite Deal. Why It Makes Sense. -- Barrons.com

14. Apr. 2026, 18:30 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

14. Apr. 2026, 18:30 UTC

Market Talk

Treasury Yields, Dollar Fall as Markets Price Higher Odds of Fed Cuts -- Market Talk

Peer-Vergleich

Kursveränderung

Lisata Therapeutics Prognose

Rating-Konsens

By TipRanks

Neutral

1 ratings

Buy

Halten

Sell

Basierend auf 1 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Lisata Therapeutics – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Gewinn vor Steuern

Verkäufe

Betriebsergebnis

Über Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.